Answers are grounded in this paper and cite their sources.
With this technology, a potent small molecule with an appropriate therapeutic window should be administrable by intravitreal injections in the human at once-monthly intervals.
No takes yet. Share an insight, caveat, or question.
Machinaga et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: